PTT 020
Alternative Names: PTT-020Latest Information Update: 02 Feb 2026
At a glance
- Originator Pyrotech Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Pyroptosis modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bladder cancer
Most Recent Events
- 13 Jan 2026 Preclinical trials in Bladder cancer in China (unspecified route) (Pyrotech Therapeutics pipeline; January 2026)